Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huofeitong tablet
- Development stage
- Phase 2
- Lead developer
- Heyuan Jinyuan Green Life
- Administration
- Oral
01
Overview
Huofeitong tablet is a traditional Chinese herbal medicine (TCM) developed by Heyuan Jinyuan Green Life Co., Ltd. for the treatment of stable chronic obstructive pulmonary disease (COPD). It is specifically formulated to address the "lung-kidney deficiency" pattern, a diagnostic category in traditional Chinese medicine. The drug has been evaluated in Phase 2 clinical trials in China (e.g., CTR20131030) to assess its safety and efficacy in improving lung function and respiratory symptoms in patients with stable COPD. As a botanical formulation, it likely contains multiple active herbal ingredients intended to work synergistically to alleviate airway inflammation and improve overall respiratory health.
- Brand names
- Huofeitong tablet
Beyond the preview
Go deeper on Huofeitong tablet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huofeitong tablet.